[Click eStock] "Deepnoid, Medical and Industrial AI Sales Begin in Earnest... Stock Price Undervalued Phase"

On the 17th, Kiwoom Securities analyzed that Deepnoid is expected to experience steep growth of over 100% annually due to its successful entry into the industrial artificial intelligence (AI) sector and the full-scale commercialization of medical AI sales.

Oh Hyunjin, a researcher at Kiwoom Securities, stated in a report on the same day, “Recently, AI technology application has been active mainly in the manufacturing industry for control and security industries and smart factory construction,” adding, “Deepnoid is solidifying its strong position in the market by proactively developing and providing AI solutions tailored to each client’s needs.”

Researcher Oh also noted, “The solution ‘DEEP: SECURITY,’ which detects hazardous items at security checkpoints, is seeing increasing demand not only from domestic airports but also from government ministries and large corporations,” and forecasted, “In the market’s early development stage, securing differentiated data through national projects will serve as a barrier to entry in the future.”

Additionally, the deep learning version solution for factory automation, ‘DEEP: FACTORY,’ was evaluated as competitive in analyzing unstructured data (such as images), where improving accuracy is difficult through existing precision medical AI technology.

He said, “After supplying to initial display and chemical companies, follow-up orders continue as application processes expand,” and added, “In particular, industrial diversification into the secondary battery industry, which is the most proactive in adopting smart factory processes recently, is expected.”

The existing business sector of medical AI is expected to lead Deepnoid’s mid- to long-term growth. Deepnoid’s cerebral aneurysm imaging diagnostic solution, ‘DEEP: NEURO,’ has completed selection as an innovative medical technology and the issuance of a public notice. It will be available for use in medical settings as a non-reimbursable service starting at the end of the year, with full-scale sales expected next year.

He analyzed, “Deepnoid’s medical AI sector aims for commercialization centered on screening centers along with solutions for pulmonary disease and lung nodule interpretation, and the strong sales power centered on institutions using the AI platform (DEEP: PHI) will enhance growth visibility.”

He continued, “With the successful entry into the industrial AI sector and the full-scale commercialization of medical AI sales, the company’s sales are expected to sharply increase to 7 billion KRW this year (120% year-over-year) and 20 billion KRW next year (186% year-over-year),” and forecasted, “Operating profit is also expected to turn positive next year at 7 billion KRW following a reduction in losses this year.”

Furthermore, he added, “Despite the large scalability of the company’s AI solutions and the trend of expanding AI technology application within the industry enabling high growth, the stock price is judged to be undervalued compared to other AI companies.”

This content was produced with the assistance of AI translation services.